Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: Results of a national survey
Journal of Antimicrobial Chemotherapy, Volume 59, No. 5, Year 2007
Notification
URL copied to clipboard!
Description
Objectives: There is an increasing interest in the possible role of fluoroquinolone antibiotics for the treatment of tuberculosis (TB), but widespread use of these antibiotics for the treatment of other bacterial infections may select for fluoroquinolone-resistant Mycobacterium tuberculosis strains. Methods: We evaluated fluoroquinolone susceptibility using the proportion method (ofloxacin, critical concentration 2.0 mg/L) in isolates from patients enrolled in a national drug resistance survey in Rwanda from November 2004 to February 2005. Results: Of the 701 M. tuberculosis isolates studied, 617 (88%) were susceptible to all first-line drugs, 32 (4.6%) were multidrug-resistant (MDR) and 52 (7.4%) were resistant to one or more first-line drugs but not MDR. Ofloxacin resistance was found in four (0.6%) of the isolates; three of them being MDR and one susceptible to all first-line drugs. Mutations in the gyrA gene were found in all ofloxacin-resistant strains at codons 80 and 94. Conclusions: Our finding is not alarming for Rwanda, but highlights the general risk of producing resistance to fluoroquinolones, jeopardizing the potential for these drugs to be used as second-line anti-TB agents in the programmatic management of drug-resistant TB and creating incurable TB strains. © The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Authors & Co-Authors
Umubyeyi, Aline Nyaruhirira
Rwanda, Butare
University of Rwanda
Belgium, Antwerpen
Prins Leopold Instituut Voor Tropische Geneeskunde
Rigouts, Leen
Belgium, Antwerpen
Prins Leopold Instituut Voor Tropische Geneeskunde
Shamputa, Isdore Chola
Belgium, Antwerpen
Prins Leopold Instituut Voor Tropische Geneeskunde
Zambia, Ndola
Tropical Diseases Research Centre
Fissette, Kristina
Belgium, Antwerpen
Prins Leopold Instituut Voor Tropische Geneeskunde
Elkrim, Y.
Belgium, Antwerpen
Prins Leopold Instituut Voor Tropische Geneeskunde
de Rijk, Pim B.
Belgium, Antwerpen
Prins Leopold Instituut Voor Tropische Geneeskunde
Struelens, Marc J.
Belgium, Brussels
Hôpital Erasme
Portaels, Françoise Ç.Oise
Belgium, Antwerpen
Prins Leopold Instituut Voor Tropische Geneeskunde
Statistics
Citations: 37
Authors: 8
Affiliations: 4
Identifiers
Doi:
10.1093/jac/dkm038
ISSN:
03057453
e-ISSN:
14602091
Research Areas
Cancer
Genetics And Genomics
Infectious Diseases
Study Design
Cross Sectional Study
Study Approach
Quantitative
Study Locations
Rwanda